In Dorset around 1,000 people currently qualify for the medication based on national eligibility criteria, which states individuals must: Have a body mass index (BMI) of 40 kg/m or more (or 37.5 kg/m for people from minority ethnic family backgrounds) and have at least four of the following long-term conditions: Non-diabetic hyperglycaemia or type 2 diabetes Hypertension (high blood pressure) Dyslipidaemia Established cardiovascular disease Obstructive sleep apnoea To find out more information please follow the link below: | The Harvey Practice
Once reconstituted, the peptide bonds become vulnerable again to aqueous hydrolysis, and oxidation of susceptible residues (tryptophan and methionine analogs in the sequence) begins
GLP-1 drugs slow gastric emptying, which means food and nutrients move through your stomach more slowly
How to manage tirzepatide side effects Most tirzepatide side effects are temporary, predictable, and respond to simple changes in your daily habits
Healthcare professionals should: Provide clear safety-netting advice about nutritional concerns Encourage maintenance of a balanced, nutrient-rich diet Consider dietitian referral for vulnerable patients Investigate and treat confirmed iron deficiency appropriately Follow NICE and BSG guidance for investigation of iron deficiency anaemia Review the risk-benefit profile of continuing Wegovy if nutritional deficiencies prove difficult to manage If patients suspect they are experiencing side effects from Wegovy, they or their healthcare professional can report these through the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk)
Injection site reactions have no correlation with medication efficacy